An Open label, balanced, randomized, two-treatment, twoperiod,two-sequence, single oral dose, crossover,bioequivalence study of FDC of Azelnidipine 8 mg +Telmisartan 40 mg tablet of Signature PhytochemicalIndustries with Uniaz T 40mg tablet (Azelnidipine 8 mg +Telmisartan 40 mg) of Synokem Pharmaceuticals Ltd., inhealthy adult human subjects under fasting conditions.

Signature Phytochemical Industries0 个研究点目标入组 28 人开始时间: 待定最近更新: 2023年4月3日

试验速览

暂无简介。

•1.Willing to provide written informed consent for participation in the study, and an ability to comprehend the nature and purpose of the study.
•2.Willing to be available for the entire study period and to comply with protocol requirements.
•3.Normal, healthy, adult, human subject of 18-55 years (both inclusive) of age.
•4.Body mass index in the range of 18 â?? 30 kg/m2 (both inclusive).
•5.Normal haemoglobin between 12.5 to 17.5 grams per deciliter (g/dL) for men and 12 to 16 g/dL for female.

•1.Found positive (+ve) on rapid test for COVID-19 during screening.
•2.Haemoglobin level less than 12.5 grams per deciliter for men and 12 grams per deciliter for women.
•3.Any medical or surgical conditions, which might significantly interfere with the functioning of the gastrointestinal tract and bloodâ??forming organs.
•4.History of gastric or duodenal ulcer or GI bleeding or blood in stools anytime in the past.

发起方